Respect others

Kerala/Los Angeles

[TheUrbanFarmer @NattaCop]

$ocgn Most will see “Phase 3 for GA in 2026” and shrug. The ones who know GA, the therapy and this market understand the gravity of what was just announced.

Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the 6 month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side.

Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market.

Why I’m saying that

OCU400 family keeps winning. OCU400 for IRDs, OCU410ST for Stargardt, and OCU410 for GA have shown consistent 100% efficacy signals with 100% safety to date. FDA’s recent CGT flexibility on self controlled designs external controls and registry follow up is also built for this platform and means a very fast path to market than anyone expects.

So why would OCU410 likely be the world’s most valuable drug and why has big pharma paid billions for early phase GA assets?
Because the numbers are staggering.
👇🍻💸🏦

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

#OCUGEN #OCU410
WE ARE SUPERIOR AT THIS STAGE COMPARED TO AVAILABLE DRUGS!!!

[HIEU TRAN the Insurance Man @HieuTrantheMAN]

$OCGN

The FUTURE is BRIGHT!

#CourageousInnovation
#RetinitisPigmentosa
#LeberCongenitalAmaurosis
#GeneTherapy #CellTherapy #OCU500 #OCU200 #OCU400 #OCU410 #NeoCart

[Ivan @IvandeaGreat]

One of the best reasons to be a part of this. Beautiful!

$OCGN

[Ocugen @Ocugen]

We’re advancing clinical research in Stargardt disease! Ocugen is now enrolling U.S. patients for our Phase 2/3 OCU410ST-101/301 trial, starting at age 3.

Learn more: NCT05956626 | [email protected]

#ClinicalTrials #StargardtDisease #GeneTherapy

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

#OCUGEN #OCU410ST
FDA would have not ever aproved the age of 3, unless there are confirmation in place for the success of this therapies!!!
THIS IS EPIC!
CONGRATULATIONS TO @Ocugen team!!!

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

#OCUGEN $OCGN....rare disease designation!
👇👇👇👇

[Mary B Schanck @MaryBschanck]

$OCGN : Back during COVID, this stock could’ve easily hit $50–$100 if big pharma and the U.S. government hadn’t blocked their vaccine. It was arguably the only one that truly worked showing just how legitimate this company is.

Now they’ve shifted gears and have a blindness gene therapy with no real competition. If it delivers as expected, $30 is just the beginning $50 to $100 is absolutely on the table. These guys know what they’re doing.

[TheUrbanFarmer @NattaCop]

$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙

[Ocugen @Ocugen]

Our CEO & Executive VP of Commercial and Business Development are featured presenters at @alliancerm's 2025 Cell & Gene Meeting on the Mesa, @ChardanCM's 9th Annual Medicines Conference, and @MaximGrp's Maxim Growth Summit!

Read more: https://t.co/zc0nlrYesH

#Genetherapy

[BRexNew @BRexNew]

All GT’s Read it!

Provides clarity on the lack of efficacy assessment tools, IRD’s, measuring successful endpoint outcomes without advancement in innovative assessment approaches like (LDNA) etc.

A breakthrough by @Ocugen 👏@drhumaqamar

https://t.co/n7miK3qjAy
#OCU400 $OCGN

[Ocugen @Ocugen]

This #VisionAwarenessMonth, we’re advancing science to address unmet needs for people facing vision loss to bring new hope worldwide.

#InnovationInSight #VisionHealth

[Respect others @Respect15447394]

@afra_art56 he is beautiful and a happy boy.
❤️❤️

[Thierry ALATOM @ThierryAlatom]

$OCGN "IND cleared" means that the FDA has reviewed an Investigational New Drug (IND) application and approved it, granting a "green light" to proceed with testing in humans ✅ 🚀
@Ocugen #covidnews

[Hamiltoeser @Mr_Yambone]

$OCGN OCU500 update. Phase 1 planned for Q3 2025. https://t.co/NeONL4cbbN

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

#OCUGEN $OCGN ..... read it and just think how close we are!!! 🤭🤭🤭

[BRexNew @BRexNew]

See highlighted para.

Critical therapies based on surrogate endpoint results from phase 2 trials, provided confirmatory phase 3 trial results are submitted later.

Phase 3 data inclusive of Expanded Access Program and Canada data.

#OCU400 #OCU410ST #OCU410GA $OCGN

[Guy @GuyCreal]

$ocgn massive short squeeze about to happen. Inked deal with Korean company for their eye gene therapy. Many more countries to follow. $20+ stock. $btc $tsla $gme $amc $bb $bbai $amzn $aapl $tnxp $gnpx @TopStockAlerts1

[Ocugen Investor @kickstarterx10]

$OCGN Ocugen’s Strategic Advancements and Promising Prospects Justify Buy Rating

https://t.co/DHgWY2ofLm

[Supplements Manufacturer 🐊🐊🐊 @MoreFlax]

#OCUGEN @Ocugen
👏👏👏👏
https://t.co/zOaVuYTaJL